Skip to main content
. 2024 Feb 15;10:79. doi: 10.1038/s41420-024-01845-3

Fig. 6. In vivo evaluation of ADCs in a mouse ectopic xenograft model.

Fig. 6

The in vivo efficacy was investigated in SCID mice implanted subcutaneous with BT-474 HER2-positive mammary tumors. A Tumor response was evaluated using single administration of 3 mg/kg dose (trastuzumab ADC or T-DM1) and tumor volume was measured at different time intervals. B Tumor response was evaluated using several administrations of various dose of antibody fragments (trastuzumab -Qtag2 -DM1 or T-DM1) and tumor volume was measured at different time intervals Mean ± SEM (n = 6). Tumor size was followed over 3 weeks. Statistical significance was calculated by unpaired one tailed t-test using GraphPad Prism 7.0b (GraphPad Software Inc., San Diego, CA, USA) software;. n.s : non significative, *P < 0.05 ***P < 0.001.